Tuesday, February 22, 2011
Conatus Pharmaceuticals Inc., of San Diego, treated the first patient in a Phase IIb trial of CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys) and ribavirin in treatment-experienced hepatitis C virus null responders. Safety, tolerability and antiviral activity of the triple combination will be assessed after up to 48 weeks. About 260 patients will be enrolled. CTS-1027 is a small molecule designed to inhibit matrix metalloproteinases.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.